| 词条 | Rimegepant |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = [(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate | image = Rimegepant.svg | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = Investigational | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1289023-67-1 | class = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 997WVV895X | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = 51049968 | ChemSpiderID = 27289072 | DrugBank = | synonyms = BHV-3000, BMS-927711 | C=28|H=28|F=2|N=6|O=3 | StdInChIKey = KRNAOFGYEFKHPB-ANJVHQHFSA-N | StdInChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1 | SMILES = C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6 }}Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb,[1] it is currently under development by Biohaven Pharmaceuticals.[2] Mechanism of actionRimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.[3] References1. ^{{Cite web | title = Drug Profile: Rimegepant | url = http://adisinsight.springer.com/drugs/800034984 | publisher = Adis Insight}} {{Signaling peptide/protein receptor modulators}}{{nervous-system-drug-stub}}2. ^{{cite web | url = http://biohavenpharma.com/rimegepant-for-acute-treatment-of-migraine/ | title = Rimegepant (BHV-3000) – for acute treatment of Migraine | publisher = Biohaven Pharmaceuticals}} 3. ^{{cite journal | doi = 10.1016/S1474-4422(15)00198-2| pmid = 26376968| title = New therapeutic approaches for the prevention and treatment of migraine| journal = The Lancet Neurology| volume = 14| issue = 10| pages = 1010| year = 2015| last1 = Diener| first1 = Hans-Christoph| last2 = Charles| first2 = Andrew| last3 = Goadsby| first3 = Peter J| last4 = Holle| first4 = Dagny}} 7 : Receptor antagonists|Carbamates|Piperidines|Fluoroarenes|Antimigraine drugs|Heterocyclic compounds (2 rings)|Nitrogen heterocycles |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。